Last reviewed · How we verify
Recombinant Influenza vaccine candidate
Recombinant Influenza vaccine candidate is a Biologic drug developed by Aramis Biotechnologies Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Recombinant Influenza vaccine candidate |
|---|---|
| Sponsor | Aramis Biotechnologies Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg (PHASE2)
- Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836 (PHASE2)
- Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. (PHASE2)
- Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1 (PHASE1)
- Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. (PHASE2)
- Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older (PHASE1)
- Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Influenza vaccine candidate CI brief — competitive landscape report
- Recombinant Influenza vaccine candidate updates RSS · CI watch RSS
- Aramis Biotechnologies Inc. portfolio CI
Frequently asked questions about Recombinant Influenza vaccine candidate
What is Recombinant Influenza vaccine candidate?
Recombinant Influenza vaccine candidate is a Biologic drug developed by Aramis Biotechnologies Inc..
Who makes Recombinant Influenza vaccine candidate?
Recombinant Influenza vaccine candidate is developed by Aramis Biotechnologies Inc. (see full Aramis Biotechnologies Inc. pipeline at /company/aramis-biotechnologies-inc).
What development phase is Recombinant Influenza vaccine candidate in?
Recombinant Influenza vaccine candidate is in Phase 1.